We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pre-market futures are averaging out to be flat at this hour, although we’re seeing a wider band of trading. The blue-chip Dow and the small-cap Russell 2000 — up +110 points and +2 points, respectively — are being slightly offset by -103 points on the tech-heavy Nasdaq and -2 on the comprehensive S&P 500 currently.
Doubts continue about the levels of AI infrastructure spending, and whether they are sustainable into the new year. On Broadband’sAVGO conference call yesterday afternoon following an otherwise robust earnings report, CEO Hock Tan saw some negative sentiment hit his company’s stock when he cited a lower-than-expected level of AI product orders next year. Tan later clarified he saw the $73 billion backlog as a minimum end of the range, but shares remain down -5% in today’s pre-market.
Next Week, Reports of Consequence: BLS, CPI
By Tuesday of next week, we’ll have a fresh catalyst for market sentiment. That’s when we’ll see the long-awaited Employment Situation report from the U.S. Bureau of Labor Statistics (BLS) for November. I say “long awaited” because we are skipping right over October’s numbers due to the month-and-a-half government shutdown. Last time around, we saw +119K new jobs created in September, with an Unemployment Rate of +4.4%.
That +119K is not a bad number, especially in our current labor market environment. It likely more than makes up for retirees per month in the domestic labor force, so essentially it’s a growth number — which is good. The trouble is, this is by far the biggest monthly jobs gain of the last four months reported. Averaged out, they only come to +44K new jobs per month — less than what our economy needs to account for Baby Boomers (and older Gen-X) retiring.
Compare this with the four previous months’ average of +100K, and +185K the four months prior to that. So we can see some clear erosion in the labor market over the past year, up until September. Since then, with corporate layoffs taking headlines and immigration crackdowns affecting domestic labor, we don’t see much opportunity for upside in the upcoming BLS report. Unemployment, at 4.4%, is the highest we’ve seen in four years, but not yet anything historically problematic.
Thursday of next week brings us the long-awaited Consumer Price Index (CPI) report, including a fresh Inflation Rate (CPI year over year, headline) for November. This print also suffered the wrath of the government shutdown and is skipping October data, and where we last left off we saw a +3.0% Inflation Rate for the first time since January.
The trend in the charts going back 2 1/2 years or so — when we finally saw inflation rates come down from multi-decade highs — demonstrate lower highs and lower lows each wave through the cycle. We were at +3.7% in September 2023, +3.5% in March of ’24, and +3.0% in January ’25 for recent highs. But CPI year over year is among the most conspicuously absent of economic prints this year, and that we reached +3.0% in September again in this latest high (so far) may portend a new narrative.
That’s why next week’s data is so important: we appear to be at a new economic impasse, and that no one knows which way things may break is what will likely give the Fed pause going into the new year. Because somewhat lost in the positive outlook for GDP growth and inflation rates through 2026 overall, it’s clear Fed Chair Jerome Powell and his assenters of the FOMC are planning to tiptoe into the next Fed meeting.
We cover more than 1,000 of the most widely followed stocks in our Equity Research Reports. Each report features independent research from our analysts and provides in-depth analysis on a company, its fundamentals and its growth prospects. Quickly access reports for New Upgrades and New Downgrades.
You can also find a report on the ticker of your choice, or access all of the stock reports covered by Zacks analysts.
The Bank of New York Mellon (BK)Upgraded: 12/12/25
Global footprint, stabilizing funding costs and a solid balance sheet position are likely to keep aiding BNY Mellon’s revenues. The company's enhanced capital distributions look sustainable.
Cencora’s specialty expansion and GLP-1 demand fuel strong revenue growth, while robust free cash flow and scale position it to capture secular healthcare market tailwinds.
TriMas will continue to gain from the strength in demand in the end markerts of its packaging segment. Focus on innovation, acquisitions and a solid balance sheet will aid growth.
Dover is poised to gain from solid order booking, cost-reduction initiatives and execution of margin targets. Further, product digitization, e-commerce, new product development will boost growth.
Boston Scientific is gaining traction in the international markets. New regulatory approvals and accretive acquisitions bode well for long-term growth.
Investments to expand existing electric and natural gas infrastructure, a focus on renewable energy and contributions from organic assets along with the increasing customer base, will act as tailwinds.
Rising healthcare spending and an aging population will aid Ventas’ senior housing operating portfolio. Also, accretive investments in the research portfolio and a solid balance sheet bode well.
Strong cash generation, investment in growth projects and higher operational efficacy aided by adoption of technology, and solid long-term outlook for metal prices bode well for BHP Group.
Upbound Group’s Rent-A-Center segment, which accounts for a significant portion of its revenues, is facing structural challenges that could limit future profitability.
Packaging Corporation of America (PKG)Downgraded: 12/06/25
Packaging Corporation's near-term results are likely to be impacted by low volumes. High maintenance outage costs are also anticipated to weigh on the company's margins in the near term.
Constellation Brands is witnessing sluggishness in its wine and spirits business for a while now. For fiscal 2026, STZ’s comparable operating income is expected to decline 9-11%.
Archer Daniels' Ag Services & Oilseeds unit struggled in third-quarter 2025 due to reduced crush margins and weaker global trade volumes. Also, stiff competition in the industry is a concern.
American Eagle remains well placed on the back of cost-reduction efforts and brand progress. In addition, its Powering Profitable Growth plan bodes well.
Innovative Medicine unit is showing a growth trend, driven by existing products like Darzalex, Tremfya and Erleada and continued uptake of new launches, including Spravato, Carvykti and Tecvayli.
Broadcom is a leading player in the semiconductor market based on its expanding product portfolio, multiple target markets, accretive acquisitions and strong cash flow.
Decent loan demand and expansion into new markets by opening financial centers are expected to support Bank of America. Also, digital enhancement will likely keep aiding cross-selling opportunities.
Strength in the Energy Generation/Storage business, balance sheet strength, and focus on autonomous driving and artificial intelligence are set to drive Tesla.
Strength across all product groups is a positive catalyst for Edwards Lifesciences. The company’s bullish long-term growth strategy buoys optimism on the stock.
Align Technology’s robust product line, balanced growth across all channels and consistent focus on international markets to drive growth bolster our confidence in the stock.